Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Champions Oncology, Inc. (NASDAQ: CSBR).

Full DD Report for CSBR

You must become a subscriber to view this report.


Recent News from (NASDAQ: CSBR)

Champions Oncology to Present at the 3rd annual Disruptive Growth & Healthcare Conference on May 9th
HACKENSACK, N.J. , May 3, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at the 3rd annual D...
Source: PR Newswire
Date: May, 03 2018 08:30
Champions Oncology Adds Amy Wesa, Ph.D, as Director of Immuno-Oncology Research
HACKENSACK, N.J. , May 1, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Amy Wesa , Ph.D, has joined the company as ...
Source: PR Newswire
Date: May, 01 2018 08:30
Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House
HACKENSACK, N.J. , April 4, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year...
Source: PR Newswire
Date: April, 04 2018 08:30
Blog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes
Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) ("Lexicon"). If you want access to this report all you need to do is sig...
Source: ACCESSWIRE IA
Date: March, 28 2018 07:10
Champions Oncology's (CSBR) CEO Ronnie Morris on Q3 2018 Results - Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q3 2018 Earnings Conference Call March 15, 2018 4:30 PM ET Executives Ronnie Morris – Chief Executive Officer David Miller – Chief Financial Officer Analysts Joshua Horowitz – Equity Group Anthony Marchese – TriPoi...
Source: SeekingAlpha
Date: March, 15 2018 21:13
Champions Oncology reports Q3 results
Champions Oncology (NASDAQ: CSBR ): Q3 EPS of $0.00 More news on: Champions Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 15 2018 16:43
Champions Oncology Reports Quarterly Revenue of $5.1 Million
HACKENSACK, N.J. , March 15, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third fiscal qua...
Source: PR Newswire
Date: March, 15 2018 16:01
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 15, 2018
HACKENSACK, N.J. , March 7, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational re...
Source: PR Newswire
Date: March, 07 2018 08:30
Champions Oncology to Participate at the 30th Annual ROTH Conference
HACKENSACK, N.J. , Feb. 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will participate at the 30th An...
Source: PR Newswire
Date: February, 26 2018 08:30
Motivated Patients with ROS1 Cancer Initiate Global Research Study
SAN CARLOS, Calif. and HACKENSACK, N.J. , Feb. 21, 2018 /PRNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (NASDAQ: CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. Th...
Source: PR Newswire
Date: February, 21 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-177.5317.917.977.53126,704
2018-08-167.287.7947.807.2522,701
2018-08-157.78887.637.797.199337,817
2018-08-147.507.8057.87267.3325,638
2018-08-137.647.507.647.3372,009

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1784210,8227.7804Cover
2018-08-1642610,2124.1716Cover
2018-08-158016,39912.5176Cover
2018-08-142,8904,35566.3605Short
2018-08-133,61013,53526.6716Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CSBR.


About Champions Oncology, Inc. (NASDAQ: CSBR)

Logo for Champions Oncology, Inc. (NASDAQ: CSBR)

Champions Oncology, Inc. the Company , is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company s TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Personalized Oncology Solutions POS and Translational Oncology Solutions TOS . POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The Company s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings.

 

 

 

Current Management

  • Joel Ackerman / CEO
  • Ronnie Morris / President
  • Gary G. Gemignani / EVP, CFO
  • David Miller / VP, Fin.
  • Susan Foreman / IR
  • Scott R. Tobin /

Current Share Structure

  • Market Cap: $38,239,448 - 03/20/2018
  • Authorized: 200,000,000 - 04/24/2015
  • Issue and Outstanding: 10,988,347 - 12/09/2017

 


Recent Filings from (NASDAQ: CSBR)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 19 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: December, 15 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: December, 15 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 07 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 07 2017

 

 


Daily Technical Chart for (NASDAQ: CSBR)

Daily Technical Chart for (NASDAQ: CSBR)


Stay tuned for daily updates and more on (NASDAQ: CSBR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CSBR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CSBR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CSBR and does not buy, sell, or trade any shares of CSBR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/